SKYSTAR
Live / Applied — Fifth extension granted (statement of use) (as of 13 Nov 2025)
What this means for you
Not registered yet, but its 17 Mar 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97316737
- Mark type
- Stylized text
- Filed
- 17 Mar 2022
- Published for opposition
- 16 May 2023
- Attorney of record
- Peter Kunin
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals, namely, small molecule therapeutic preparations for the correction of RNA expression, used in the treatment of cancers, and other diseases, namely, cardiovascular diseases, immunological diseases, autoimmune diseases, neuromuscular diseases, blood disorders, rare genetic disorders and fibrosis; pharmaceuticals used in the treatment of cancers, and other diseases, namely, cardiovascular diseases, immunological diseases, autoimmune diseases, neuromuscular diseases, blood disorders, rare genetic disorders and fibrosis
Owner
- Skyhawk Therapeutics, Inc., Waltham, MA, US
- Skyhawk Therapeutics, Inc., Waltham, MA, US
Prior registrations
Prosecution history
- 14 Nov 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Nov 2025 — SOU EXTENSION 5 GRANTED
- 05 Nov 2025 — SOU EXTENSION 5 FILED
- 06 Nov 2025 — SOU TEAS EXTENSION RECEIVED
- 17 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 16 May 2025 — SOU EXTENSION 4 GRANTED
- 08 May 2025 — SOU EXTENSION 4 FILED
- 09 May 2025 — SOU TEAS EXTENSION RECEIVED
- 31 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 31 Oct 2024 — SOU EXTENSION 3 GRANTED
- 31 Oct 2024 — SOU EXTENSION 3 FILED
- 31 Oct 2024 — SOU TEAS EXTENSION RECEIVED
- 24 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Jun 2024 — SOU EXTENSION 2 GRANTED
- 24 Jun 2024 — SOU EXTENSION 2 FILED